Figure 7
Figure 7. The chemotactic activity of CXCL4L1 for human immature DCs is mediated via CXCR3. To demonstrate the involvement of CXCR3 in immature DC chemotaxis, cells were preincubated with CXCR3 ligands [(A) 30 ng/mL CXCL4, 30 ng/mL CXCL4L1, 50 ng/mL CXCL10, 20 ng/mL CXCL11, or dilution buffer (Ctrl)] or CXCR3-neutralizing Abs [(B) dilution buffer (Ctrl), 10 μg/mL monoclonal Ab (mAb), 28 μg/mL polyclonal Ab (pAb), or 10 μg/mL isotype control Ab] before addition to the Boyden microchamber. As chemoattractants, CCL3 (100 ng/mL), CXCL4 (30 ng/mL), CXCL4L1 (30 ng/mL), CXCL10 (50 ng/mL), or CXCL11 (20 ng/mL) were added to the lower wells. Results shown are the mean ± SD from 4 (A) or 3 (B) independent experiments. In panel A, statistically significant reduction of migration is indicated (*P < .05; Mann Whitney test).

The chemotactic activity of CXCL4L1 for human immature DCs is mediated via CXCR3. To demonstrate the involvement of CXCR3 in immature DC chemotaxis, cells were preincubated with CXCR3 ligands [(A) 30 ng/mL CXCL4, 30 ng/mL CXCL4L1, 50 ng/mL CXCL10, 20 ng/mL CXCL11, or dilution buffer (Ctrl)] or CXCR3-neutralizing Abs [(B) dilution buffer (Ctrl), 10 μg/mL monoclonal Ab (mAb), 28 μg/mL polyclonal Ab (pAb), or 10 μg/mL isotype control Ab] before addition to the Boyden microchamber. As chemoattractants, CCL3 (100 ng/mL), CXCL4 (30 ng/mL), CXCL4L1 (30 ng/mL), CXCL10 (50 ng/mL), or CXCL11 (20 ng/mL) were added to the lower wells. Results shown are the mean ± SD from 4 (A) or 3 (B) independent experiments. In panel A, statistically significant reduction of migration is indicated (*P < .05; Mann Whitney test).

Close Modal

or Create an Account

Close Modal
Close Modal